Andere Sprachen Ascendis Pharma A/S

Aktien

A14M6X

US04351P1012

ASND

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 24.04.2024			% 5 Tage	% 1. Jan.
143.2 ^USD	-1.14%		+0.71%	+13.68%

24.04.	Ascendis Pharma erhält UK-Zulassung für Yorvipath zur Behandlung von Hypoparathyreoidismus	MT
19.04.	Europäische Aktien, die in den USA als American Depositary Receipts gehandelt werden, tendieren im Freitagshandel höher, beenden die Woche aber mit einem Minus	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism	24.04.
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism	24.04.
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	19.04.
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	18.04.
Ascendis Pharma A/S : Form 6-K	10.04.
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday	28.03.
Ascendis Pharma A/S : Form 6-K	27.03.
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	21.03.
Ascendis Pharma A/S : Form 6-K	14.03.
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	13.03.
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	12.03.
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024	04.03.
Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer	29.02.
European Equities Traded in the US as American Depositary Receipts Set to End Week Higher in Friday Trading	16.02.
European Equities Traded in US as American Depositary Receipts Move Slightly Higher in Friday Trading	09.02.
Ascendis Pharma Q4 Net Loss Narrows, Revenue Rises	07.02.
Earnings Flash (ASND) ASCENDIS PHARMA Posts Q4 Revenue EUR137.7M	07.02.
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results	07.02.
Ascendis Pharma A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07.02.
Ascendis Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2023	07.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ascendis Pharma A/S

Aktien

A14M6X

US04351P1012

ASND

Andere Sprachen

Filter